For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for West Pharmaceutical Services Inc. (WST) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-10-08): Designation Low · Gem Score -36 (−100…+100 Quality+Value blend) · Quality 21 · Value -74 · Sentiment -31 (timing only, not weighted) · Composite fair value $75.92 vs $342.63 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
West Pharmaceutical Services Inc.
WST NYSEWest Pharmaceutical Services Inc. is a healthcare products manufacturer focused on the design, development, and production of containment and delivery systems for injectable drugs and other healthcare products. The company supplies critical components such as stoppers, seals, syringe and cartridge parts, reconstitution and transfer systems, safety and administration devices, and advanced injection solutions that support the packaging and delivery of pharmaceuticals and biologics. It also provides contract manufacturing and analytical lab services through its proprietary and contract-manufactured product segments. West Pharmaceutical Services Inc. serves a broad customer base that includes pharmaceutical, biotechnology, generic-drug, medical device, and consumer healthcare companies. Headquartered in Exton, Pennsylvania, the company plays an important role in the healthcare supply chain by helping enable safe, reliable, and efficient delivery of injectable therapies worldwide.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 6.79
Total Equity: $3.18B
Shares: 72,700,000
Total Debt: $206.40M
Cash: $791.30M
EBITDA: $756.30M
Total Debt: $206.40M
Cash: $791.30M
Revenue: $3.07B
Revenue: $3.07B
Revenue: $3.07B
Total Equity: $3.18B
Tax Rate: 20.2%
Equity: $3.18B
Total Debt: $206.40M
Cash: $791.30M
Current Liabilities: $654.90M
Long-Term Debt: $206.40M
Total Debt: $206.40M
Total Equity: $3.18B
Shares: 72,700,000
Shares: 72,700,000
CapEx: -$285.90M
Shares: 72,700,000
Stock Price: $342.63
Net Income: $493.70M
Industry Benchmarks
Income Statement (Annual)
Last updated: Sep 3, 2026 4:55am (35d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $2.8B | $2.9B | $2.9B | $2.9B | $3.1B |
| Cost of Revenue | $1.7B | $1.8B | $1.8B | $1.9B | $2.0B |
| Gross Profit | $1.2B | $1.1B | $1.1B | $998.5M | $1.1B |
| Operating Expenses | $423.5M | $402.2M | $453.2M | $428.6M | $519.1M |
| Operating Income | $752.3M | $734.0M | $676.0M | $569.9M | $584.9M |
| Net Income | $661.8M | $585.9M | $593.4M | $492.7M | $493.7M |
| EBITDA | $874.6M | $854.6M | $813.3M | $725.3M | $756.3M |
| EPS | $8.89 | $7.87 | $7.98 | $6.75 | $6.83 |
| EPS (Diluted) | $8.67 | $7.73 | $7.88 | $6.69 | $6.79 |
Balance Sheet (Annual)
Last updated: Sep 3, 2026 4:30am (35d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $762.6M | $894.3M | $853.9M | $484.6M | $791.3M |
| Total Current Assets | $1.7B | $1.9B | $1.9B | $1.5B | $2.0B |
| Total Assets | $3.3B | $3.6B | $3.8B | $3.6B | $4.3B |
| Current Liabilities | $594.1M | $519.0M | $671.8M | $550.4M | $654.9M |
| Long-Term Debt | $208.8M | $206.7M | $72.8M | $204.7M | $206.4M |
| Total Liabilities | $978.4M | $931.9M | $948.5M | $961.1M | $1.1B |
| Total Equity | $2.3B | $2.7B | $2.9B | $2.7B | $3.2B |
| Retained Earnings | $2.5B | $3.0B | $3.5B | $4.0B | $4.4B |
Cash Flow (Annual)
Last updated: Sep 3, 2026 4:55am (35d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $584.0M | $724.0M | $776.5M | $653.4M | $754.8M |
| Capital Expenditure | -$253.4M | -$284.6M | -$362.0M | -$377.0M | -$285.9M |
| Free Cash Flow | $330.6M | $439.4M | $414.5M | $276.4M | $468.9M |
| Acquisitions (net) | — | — | — | — | — |
| Net Debt Issued / (Repaid) | $0 | -$1.2M | -$2.3M | -$4.3M | $0 |
| Dividends Paid | -$51.1M | -$54.1M | -$57.0M | -$59.1M | -$61.2M |
| Stock Buybacks | -$137.1M | -$202.8M | -$438.3M | -$560.9M | -$134.0M |
| Net Change in Cash | $147.1M | $131.7M | -$40.4M | -$369.3M | $306.7M |
Growth Trends (YoY %)
Last updated: Sep 3, 2026 4:55am (35d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +2.0% | +2.2% | -1.9% | +6.3% |
| Gross Profit Growth | -3.4% | -0.6% | -11.6% | +10.6% |
| Operating Income Growth | -2.4% | -7.9% | -15.7% | +2.6% |
| Net Income Growth | -11.5% | +1.3% | -17.0% | +0.2% |
| EBITDA Growth | -2.3% | -4.8% | -10.8% | +4.3% |
Dividend History (Last 20)
Last updated: Aug 31, 2026 10:22am (38d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-07-29 | $0.22 | — | — | — |
| 2026-04-29 | $0.22 | — | — | — |
| 2026-01-28 | $0.22 | — | — | — |
| 2025-11-12 | $0.22 | — | — | — |
| 2025-07-30 | $0.21 | — | — | — |
| 2025-04-30 | $0.21 | — | — | — |
| 2025-02-07 | $0.21 | — | — | — |
| 2024-11-13 | $0.21 | — | — | — |
| 2024-07-31 | $0.20 | — | — | — |
| 2024-04-23 | $0.20 | — | — | — |
| 2024-01-30 | $0.20 | — | — | — |
| 2023-11-07 | $0.20 | — | — | — |
| 2023-07-25 | $0.19 | — | — | — |
| 2023-04-25 | $0.19 | — | — | — |
| 2023-01-24 | $0.19 | — | — | — |
| 2022-11-08 | $0.19 | — | — | — |
| 2022-07-19 | $0.18 | — | — | — |
| 2022-04-19 | $0.18 | — | — | — |
| 2022-01-18 | $0.18 | — | — | — |
| 2021-11-09 | $0.18 | — | — | — |
Deep Analysis
Risk : Reward — upside vs downside from this company's own quarters
Not computed yetNarrative Economics
market-narrative step).
Growth Outlook
Analyzed 2026-09-03 05:06The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
West's raw numbers tell a more nuanced story than the "commodity components maker at 50x" bear frame suggests. The recent quarterly trajectory is genuinely inflecting: Q2 2026 revenue of $872M is up 13.8% YoY vs Q2 2025's $766M, and Q1 2026's $845M was up 21% YoY vs the depressed $698M Q1 2025 print. Net margins have re-expanded from a trough of 12.9% in Q1 2025 back to 17.7% in Q2 2026 — that's not a flat business, that's a business emerging from destocking with operating leverage kicking in. Annualizing the last two quarters gives ~$3.43B revenue vs 2025's $3.07B (roughly 12% growth), and TTM net income is running near $565M vs 2025's $494M. The synthesis engines are anchored on the 5-year CAGR (2.1% revenue, -8.8% earnings) that includes the 2023-24 COVID destocking hangover — a stale regime read.
That said, the valuation synthesis is directionally correct even if the $124 fair value is punitive. At $342, WST trades at 51x TTM earnings, ~7x EV/sales, and roughly 51x FCF ($24B market cap / $469M 2025 FCF). Even if you underwrite 12% revenue growth and full margin recovery to 2021's $661M NI level, forward P/E is still ~36x. ROIC of 18% is good but not extraordinary for a specialty industrial, and the 2021 op margin peak of 26.6% vs 2025's 19% suggests the "return to peak" narrative has real gravitational resistance from customer consolidation and pricing pressure. The $124 DCF assumes mid-single-digit growth in perpetuity — plausibly too harsh, but doubling it to $250 still leaves 27% downside from spot. I can't construct a defensible bull case above $280 without assuming 15%+ FCF CAGR for 7 years, which requires the GLP-1 narrative to fully deliver.
The insider activity is telling in what's absent: only option exercises, in-kind tax withholdings, and small awards — zero open-market buys. Executives with visibility into GLP-1 order books are not backing up the truck at $340. Combined with the fact that Q4 2025 net income ($132M) was actually flat vs Q4 2024 ($130M) despite the biologics tailwind, the "structural inflection" narrative shows cracks. The market narrative model's platform-monopoly framing is overstated — WST is a strong oligopolist with switching costs (regulatory qualification lock-in on primary packaging is real), but it competes with Aptar, Datwyler, and Stevanato, and the moat is "expensive to displace" not "impossible to displace." Narrative durability rated moderate feels right; this isn't a cult stock, it's a quality-comp trade that got carried by the GLP-1 storyline.
I partially agree with the synthesis: overvalued, yes, but $124 fair value is too aggressive a snapback given the visible reacceleration and legitimate quality attributes (net cash balance sheet, 18% ROIC, 3x current ratio, mission-critical products). My fair value lands closer to $210-240 — call it 28x normalized ~$620M earnings — which still implies 30-38% downside. The contrarian counter is that if Q3 and Q4 2026 print >$880M revenue with 18%+ margins, the 12-month forward EPS ramps to ~$9 and the multiple can stay elevated on reaccelerating growth — but that's the bull needing to be right on both volume AND margin AND multiple maintenance simultaneously. The thesis evaluation's -7 score understates how asymmetric the risk is: the bull case requires perfection, the bear case just requires reversion. I'd wait for either a $250 handle or two more quarters of >15% revenue growth with margins holding 17%+ before touching this.
GPT Reading
West is a very good business trading at an excellent-business price, and the distinction matters. The operating profile is sturdy: 2025 revenue was $3.07 billion, up just 6.2% from $2.89 billion in 2024, while net income was basically flat at $493.7 million versus $492.7 million. That follows a more telling three-year pattern: revenue has gone nowhere meaningful since 2021’s $2.83 billion, but net income has fallen from $661.8 million in 2021 to $493.7 million in 2025. So investors today are paying 50.5x earnings, 8.1x sales, and 32x EV/EBITDA for a company whose four-year revenue CAGR is about 2% and whose earnings power is still well below peak. The raw data says recovery, not breakout: the last four quarters sum to about $3.26 billion of revenue and $564.7 million of net income, better than 2025, but that only gets you to a forward-ish P/E still in the low-40s at the current $24.1 billion market cap. That is hard to justify for a packaging-and-delivery components supplier, even one with real quality and customer stickiness.
The quarterly trend is undeniably better, but it does not rescue the valuation. Revenue has improved from $698.0 million in Q1 2025 to $872.3 million in Q2 2026, and net margin recovered from a trough 12.9% to 17.7%. On a year-over-year basis, Q2 2026 revenue grew 13.8% from $766.5 million and net income grew 16.8% from $131.8 million, which is healthy. But the important point is where margins sit relative to history: 2025 gross margin was 35.9%, down from 39.1% in 2023 and 41.8% in 2021; operating margin was 19.0% in 2025 versus 26.6% in 2021. Even after the recent rebound, West is still earning structurally less on each dollar of revenue than it used to. If the market were paying 22-28x earnings for a de-risking recovery, I could entertain the secular-growth argument. At 50x trailing earnings and nearly 8x revenue, the stock already assumes not just cyclical normalization but a return to something like premium-compounder economics.
That premium is especially aggressive because the cash-flow picture, while solid, is not explosive. Operating cash flow of $754.8 million on $3.07 billion of revenue is good, and free cash flow of $468.9 million is respectable after a heavy $285.9 million of capex. The balance sheet is pristine, with $791.3 million of cash against only $206.4 million of debt, so there is no solvency issue and no hidden financial stress. But that actually sharpens the valuation problem: when the bear case on a stock is not “the business is weak” but “the business is fine and the multiple is absurd,” you need extraordinary growth to outrun the entry price. West’s ROIC at 18.0% and ROE at 15.5% are strong, yet not so exceptional that 7.8x book and 32x EBITDA look routine. This is a high-quality medtech-adjacent manufacturer being priced more like a scarce software-like platform.
The best argument against my bearish read is that the recent numbers may be the beginning of a much stronger earnings reacceleration than the annual history captures. Sequential revenue moved from $804.6 million in Q3 2025 to $805.0 million, then $844.9 million, then $872.3 million, and net income has risen with it from $132.1 million to $138.8 million to $154.0 million. If GLP-1 and biologics exposure is creating a real multiyear volume step-up, then annualized earnings based on the last two quarters could keep climbing, and a company with West’s qualification barriers, mission-critical products, and customer embedment can deserve a sustained premium. The fortress balance sheet also means management can keep investing through the cycle, and the low payout ratio of 12.4% leaves plenty of room for buybacks or dividend growth. In other words, a smart bull would say the peak-to-trough comparison against 2021 overstates “structural” margin loss and understates the earnings power once utilization improves.
What would change my mind is not another quarter of mid-teens revenue growth by itself; it is proof that growth and margin expansion can coexist at scale. I would need to see annual revenue clearly above $3.5 billion, gross margin back toward 38-40%, and net income running north of $650 million without a balance-sheet-fueled EPS trick. That would show West is not merely recovering from a soft patch but building a genuinely higher earnings base. Short of that, if the next few quarters show revenue still in the $850-900 million range but net margin stuck around 16-18%, then today’s $342 price is too high for the actual economics on display.
Grok Reading
The raw numbers describe a high-quality industrial franchise that peaked years ago and has not reclaimed that peak, yet trades as if it has already done so and then some. Annual revenue crawled from $2.83B in 2021 to $3.07B in 2025—a 2.1% CAGR—while net income fell from $661.8M to $493.7M and operating profit slid from $752M to $585M. Gross margin compressed from the low-40s toward 35.9%, operating margin from roughly 26% to 19%. Free cash flow of $468.9M on a $24.1B enterprise is a 1.9% FCF yield; at 50× trailing earnings, 8.1× sales and 32× EV/EBITDA the market is paying growth-stock multiples for mid-single-digit top-line recovery and still-subdued profitability. The sequential story is better—Q2 2026 revenue of $872M and 17.7% net margin mark a clear bounce from the soft 2025-Q1 trough—but even annualizing the last two quarters leaves you with a low-teens earnings run-rate that does not support a $343 price without heroic multi-year compounding assumptions the historical data simply do not contain.
What stands out is the gap between the balance-sheet quality and the income-statement trajectory. Net cash of roughly $585M, debt-to-equity of 0.065, current ratio above 3.0, ROIC of 18% and clean FCF conversion are the hallmarks of a durable specialty supplier with real regulatory lock-in in elastomers, stoppers and containment. That franchise is not broken. It is, however, no longer expanding the way the 2021–22 cohort of buyers expected: earnings CAGR is –8.8%, and the “GLP-1 volume tsunami” has so far produced only a 6.3% recent revenue bounce and essentially flat year-over-year earnings. The quantitative models’ ~$124 fair-value anchor is harsh but directionally honest; the $342 print embeds a structural re-rating to pharma-infrastructure monopoly status that the last five years of reported results have not validated.
The strongest opposing case is that the trough is behind us and the next five years will look nothing like the last five. Bulls will correctly note that H1 2026 revenue is already running ~15–20% above the 2025 first-half pace, net margins have re-expanded into the mid-teens, and the installed base of high-value delivery systems plus biologics/GLP-1 fill-finish demand can drive a multi-year volume and mix upcycle that the trailing CAGRs miss. A true return toward 22–24% operating margins on a $4B+ revenue base by 2028–29, plus the fortress balance sheet, could justify a mid-30s multiple and close a large part of the gap to today’s price. I weigh that case as real but insufficient: it still requires both sustained double-digit volume growth and full margin recovery simultaneously, while customer consolidation and competitive capacity remain visible risks, and the current 50× multiple leaves almost no room for a slower or lumpier path.
I would flip to a more constructive stance on two concrete triggers: four consecutive quarters of organic revenue growth above 10% with operating margins sustainably back above 22%, or clear multi-year contract disclosures that lock in GLP-1/device volumes large enough to support a credible path to $700M+ FCF within three years. Absent those, the stock remains a high-quality compounder priced for perfection that the reported economics have not delivered.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
West is a mature, self-funding business: $3.07B revenue in 2025, $468.9M FCF, $791.3M cash against modest debt (net cash $584.9M), and an Altman Z of 16.2 that puts survival risk off the table. Earnings integrity is clean — OCF/NI 1.26x, accruals -3.4% of assets, Beneish M -2.79 — so the reported profits are backed by cash. Capital return is disciplined: diluted shares have shrunk from 76.3M to 72.7M (-1.2% CAGR) with buybacks running 1,160% of the modest 0.8%-of-revenue SBC, so per-share value is being concentrated rather than leaked. Insider tape shows only routine option-exercise/tax-withholding and awards; no open-market P or S of consequence. The concern is trajectory, not solvency. Gross margin has compressed every year from 41.5% (2021) to 35.9% (2025), and operating margin has fallen from 26.6% to 19.0% over the same window. Net income peaked at $661.8M in 2021 and has since drifted to $493.7M despite revenue growing ~8% cumulatively — classic operating deleverage, not a one-off. FCF also dipped to $276.4M in 2024 before recovering to $468.9M in 2025, suggesting some working-capital/capex lumpiness rather than structural break. Durability appears real (containment components for injectable drugs is a sticky, regulated niche), but the numbers say the business has given back a meaningful chunk of its pandemic-era earnings power and has not yet demonstrated the margin has stabilized.
Verify before trusting this (5)
- Whether the gross-margin decline reflects mix shift (fewer high-margin COVID-related components) or structural pricing/cost pressure
- Segment-level margins (Proprietary Products vs. Contract-Manufactured Products) to isolate where the compression sits
- Capex intensity and any capacity-expansion program that could be depressing near-term FCF and margins
- Customer concentration in high-value injectable/biologic packaging
- Any impairment, restructuring, or one-time charges embedded in 2024 operating margin
The e2e composite pegs deserved value at $119.86 (signal-adjusted $123.94), with DCF at $82.71 and EPV floor at $71.47 — all a fraction of today's $342.63. Even the most generous input, an anchored P/E at $242.54, sits ~29% below the market price. That anchored number is the only one within shouting distance of reality and implicitly assumes normalized earnings power well above trailing results, which is exactly what the bear case disputes given a ~760 bps operating-margin slide since 2021 and net income still below the 2021 peak. Quality is genuinely strong (score 21), and I will lift deserved value for that — but even generously blending anchored-PE with the cash-flow methods lands me in the $150-$200 zone, not $340. The gap is the market capitalizing GLP-1 volumes and premium mix as permanent, alongside a re-expansion of margins that has not yet shown up in the numbers. To justify $342 you need sustained double-digit topline plus a full margin recovery to prior peak — a heroic combo when margins have compressed four straight years. Earnings quality is high, so no haircut there, but high-quality earnings at 2.7x deserved value is still expensive earnings. This is a wonderful franchise at a full price; the mispricing edge runs the wrong way.
Verify before trusting this (5)
- Forward guidance on high-value product mix and GLP-1 device volumes
- Gross-margin trajectory and whether 2021 peak is recoverable or structurally lower
- Capex intensity for new capacity and utilization ramp
- Customer concentration disclosure and pricing pressure from consolidation
- Any one-time cost items masking underlying operating leverage
WST rides a strong platform-monopoly narrative built on GLP-1 injectable demand, and that story is what has taken the stock to $342 against a DCF anchor near $124. The narrative is still 'strong' in intensity but only 'moderate' in durability, and the tape is offering nothing to reinforce it: no fresh WST-specific news in the 72-hour flow, momentum flat, 3-year growth decelerating 4pp. When the story stops getting new fuel, a story-priced stock quietly bleeds. The medtech news around it (Stryker, Enovis, GEHC, Merit) is competitor M&A and product wins, not tailwinds that lift WST. Macro is a mild net negative for this profile: 10y at 4.79% and market PE 25.8 pressure long-duration, high-multiple compounders, and with beta 1.14 WST takes a slightly amplified hit from any risk-off wobble. VIX 15 and S&P only 1.7% off highs mean the tape is calm, not supportive; there is no risk-on euphoria to re-inflate the GLP-1 trade here. Net: the pressure is asymmetric to the downside because the narrative has to keep delivering to justify the multiple, and right now nothing is delivering it.
Verify before trusting this (5)
- Any GLP-1 volume guidance revisions from Lilly or Novo that would refresh or crack the WST demand story
- Sell-side target revisions or downgrades citing normalization risk
- Whether the 10y breaks above 5% (would intensify multiple compression on this profile)
- Sector rotation into or out of high-multiple medtech vs cheaper hospital/services names
- Any capacity or competitor announcement (Aptar, SCHOTT) that would puncture the monopoly framing
The world is shifting toward injectable biologics and self-administration, which structurally expands the containment/delivery component pool West sits in — that is a tailwind independent of any single drug. Against it: mature ~4.5% industry growth, a sector demand cycle already flagged as slowing, macro headwinds with 10y at 4.79% raising the bar on the heavy capacity spend West has committed, and pharma supply-chain reshoring/tariff pressure that cuts both ways (more onshore qualification work, higher input and plant cost). Net: the end-market direction is favorable and durable, but the pace is mid-single-digit, not exponential.
When we made this prediction on Sep 3, 2026, WST was $340.39. We expect it to be $300.00 by Mar 2027, and we consider it great value under $210.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Sep 3, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.